Shenzhen Majory Biotechnology Co., Ltd.
Clinical trials sponsored by Shenzhen Majory Biotechnology Co., Ltd., explained in plain language.
-
New drug combo tested for Tough-to-Treat pancreatic cancer
Disease control Recruiting nowThis study is testing a new drug called MR001, given alongside standard chemotherapy, for people with advanced pancreatic cancer that has gotten worse after their first treatment. The main goals are to find a safe dose of MR001 and to get an early look at whether the combination …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat breast cancer: early trial tests promising drug
Disease control Recruiting nowThis study is testing a new drug called MR001 for people with advanced triple-negative breast cancer that has continued to grow despite previous treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC